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EDITORIAL REVIEW
Genetic factors in focal segmental glomeruloscierosis
Focal segmental glomerular hyalinosis and sclerosis (FGS) is
the histological description of a form of glomerular injury that is
usually associated with proteinuria and progressive loss of renal
function (Fig. 1). Originally FGS was described in nephrotic
patients who had died in end stage renal failure [1]. Rich's
observation of FGS in a group of nephrotic children who had
developed renal insufficiency [2] led some to believe that this
glomerular lesion was a prognostic ominous complication of
minimal change disease, but others consider FGS as a separate
entity altogether [3]. A large number of clinical studies and
reviewing reports on the subject of FGS have pointed out that
apart from the classical picture of the young individual who
presents with corticoid resistant or frequently relapsing ne-
phrotic syndrome associated with non-selective proteinuria,
hematuria, hypertension and progressive renal failure (idio-
pathic FGS), FGS may be a final common pathway in the
glomerulus in a number of systemic and renal diseases [3—10].
While it is realized that in most cases of human FGS, particu-
larly FGS associated with idiopathic nephrotic syndrome, the
cause of the underlying disease remains uncertain, recent
studies point to an interplay of hemodynamic, inflammatory and
genetic factors in the development of the lesions.
Experimental studies have also shown that the lesion of FGS
in laboratory animals can be induced by a variety of stimuli and
that it is usually associated with the eventual development of
progressive renal failure. In this paper we will briefly discuss
some of the mechanisms involved in the pathogenesis of FGS
and review in some detail experimental and clinical studies that
invoke an important genetic component to the development of
the lesion. Because most studies on genetic factors in FGS have
examined primarily the hemodynamic component of glomerular
injury, we have emphasized in our review of pathogenesis the
evidence implicating such factors in the evolution of FGS.
Pathogenesis of FGS
Based on the data from the literature that patients who had
lost part of their functional renal mass to whatever initial
damage, would progress inevitably to renal failure [11, 12] and
that a similar course associated with development of FGS—like
lesions had been observed in laboratory animals with or without
surgical or dietary intervention [13—23], Brenner and co-work-
ers set out to study glomerular structural and functional alter-
ations in response to renal and/or systemic diseases in labora-
tory animal models. In a series of experiments in Munich Wistar
rats after partial ablation of renal mass—the so-called remnant
kidney model—in streptozotocin—induced diabetes mellitus and
in desoxycorticosterone (DOC)-salt hypertension, they showed
Received for publication June 11, 1985,
and in revised form September 18, 1985
© 1986 by the International Society of Nephrology
the development of proteinuria and FGS—like lesions to be
associated with increased glomerular flows and pressures
[24—28].
From their observations they concluded [29—31] that the
changes in intraglomerular hemodynamics observed in these
experimental models develop as a consequence of afferent and
efferent dilatation, opening up the glomerular capillary network
to systemic blood pressure. This would lead to expansion of
glomerular volume, to increased transcapillary movement of
solute and proteins associated with capillary wall damage, and
to mesangial accumulation of macromolecules. This concept is
concordant with findings of other investigators who studied
adaptation in renal function and the development of FGS—like
lesions in the rat in the remnant kidney model [32—35], in
experimental diabetes meffitus [36—38], in experimental hyper-
tension [39—44], in glomerulonephritic models [45, 46], in ge-
netic obesity models [49—52] and in models in which combina-
tions of diseases were studied [37, 40, 47, 53—57].
Some of these studies describe increased delivery of macro-
molecules to the mesangial area as one of the consequences of
glomerular hyperperfusion [25, 28, 35, 36]. Mesangial accumu-
lation of macromolecular substances due to increased delivery
is also found in aminonucleoside nephrosis [58—61], which in its
chronic form is characterized by FGS—like lesions and progres-
sive renal failure [58]. The model of aminonucleoside nephrosis,
however, is not associated with increased intraglomerular flows
or pressures [60, 62] and mesangial accumulation of macromol-
ecules has been attributed to a direct toxic effect of
aminonucleoside on the mesangial cells [59], possibly through
an effect of angiotensin II [63].
Studies on dietary or therapeutic intervention lend further
support to the role of hemodynamics in the development of
FGS. High protein intake has been shown to increase GFR and
RPF in man and in experimental animals [29, 64—72], possibly
through suppression of the tubuloglomerular feedback system
[73]. High dietary protein aggravates the development of FGS
in different experimental models [21—28], whereas restriction of
protein ameliorates the disease [24—28]. Recent prospective
studies in man have also shown that protein restriction has a
beneficial effect on the evolution of chronic renal disease
[74—76].
Treatment of systemic hypertension and of elevated
intraglomerular pressures by converting enzyme inhibition pro-
tects the glomerulus from damage in the remnant kidney [77, 78]
as well as in chemically induced diabetes mellitus [79]. Con-
verting enzyme inhibition decreases intraglomerular pressures
while preserving flows and filtration [78]. This indicates that
increased glomerular pressure is the most dominant hemody-
namic damaging factor in the development of FGS. Control of
systemic hypertension alone does not prevent glomerular
hyperperfusion nor the development of FGS in DOC-salt hyper-
tensive rats [801.
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Fig. 1. Light micrograph of a glomerulus showing segmental hyalinosis and sclerosis. Methenamine silver, 400x.
Diets rich in the prostaglandin precursor linoleic acid have
been shown to improve renal function and to decrease protein-
uria and blood pressure in rats with reduced renal mass [81, 82],
probably through vasodilation and decreased intraglomerular
pressure.
Taking all these data together, one could conclude that
glomerular hypertension due to disproportionate afferent dila-
tion plays a crucial role in the development of FGS [83, 84]. The
interplay between afferent and efferent resistance and its effect
on intraglomerular hemodynamic forces results from several
determinants which are governed by local structural and local
as well as systemic functional, hormonal or vasoactive factors
as has been reviewed recently by Dworkin, Ichikawa and
Brenner [85] and by Navar and Rosivall [86]. Primary tubular,
vascular, hormonal and neurogenic alterations as well as ge-
netic factors may influence the sensitivity and reactivity of
these determinants as will be discussed below. In addition to
hemodynamics, other factors involved in the pathogenesis of
FGS are considered to be intrinsic properties of mesangial cells
and their reactions to accumulated macromolecules 158, 61,
87—92], dietary factors as reviewed previously [93], and coagu-
lation and platelets [15, 34, 94, 95]. Purkerson et al [34]
demonstrated that treatment of the remnant kidney in the rat
with a selective thromboxane inhibitor resulted in amelioration
of proteinuria and histological changes, without affecting high
GFR and RPF. This beneficial effect could be attributed to the
anticoagulative properties of the inhibitor and supports previ-
ous studies on the effect of anticoagulant therapy using heparin
[94, 95] and warfarin [94]. However, thromboxane inhibitors
are also potent vasodilators and may therefore exert a similar
effect on intraglomerular hemodynamics as converting enzyme
inhibitors [77—79], resulting in decreased intraglomerular pres-
sures while maintaining GFR and RPF.
Extrapolating the glomerular hemodynamic overload concept to
the clinical situation, one can postulate a satisfactory [though not
exclusive] explanation for the pathogenesis of FGS secondary to
loss of renal mass due to a variety of diseases as pointed out by
Baldwin [83] and by Brenner [84]. Interestingly however, not all
patients who have lost a considerable amount of functional renal
mass due to trauma, surgery, agenesis, glomerulonephritis, etc.,
or who suffer from hypertension, diabetes meffitus or obesity, will
develop clinical and morphological features of FGS. The reasons
for these discrepant responses may be manyfold and comprise,
among others, the extent of functional reserve capacity of remain-
ing kidney tissue, different environmental factors and probably a
number of genetic factors.
Genetic factors in FGS
In idiopathic FGS, a genetically determined susceptibility has
been suggested by the occurrence of the disease in siblings,
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although the reported cases have been rare [96—99]. A stronger
indication of genetic predisposition, possibly HLA-linked, has
been derived from data of the transplant population. FGS has
been shown to recur after transplantation at a rate of 35 to 50
per cent in large series of patients [100, 101]. In one of these
studies [100], recurrence rate was shown to be much higher in
the patients receiving the transplant from living related donors
as compared to those who received a cadaveric kidney [64 to 35
per cent response]. Within the living related transplants, recur-
rence rate of FGS was 82 per cent for four—antigen sibling
matches, whereas the 53 per cent recurrence rate for living—re-
lated transplants with less than a four—antigen match was not
statistically different from the cadaveric group [100].
A number of diseases associated with the development of
FGS or FGS—like lesions are known to bear a genetic trait, e.g.,
several forms of renal dysplasia including segmental renal
hyperplasia [102] and oligomeganephronia (unpublished obser-
vation, J D Elema), familial dysautonomia [103], hereditary
nephritis (Alport's syndrome) [8], and entities such as diabetes
mellitus [104] and essential hypertension [105]. In addition, sex
may be an important factor. Most clinical studies on FGS
describe a slight male predominance. Newman et al [106] found
an equal distribution of males and females in a pediatric group
of 16 patients, but a strong male preponderance in a group of 17
adults. Three retrospective studies on the development of
hypertension, proteinuria and/or histological features of FGS in
patients with unilateral renal agenesis [107] and in patients after
unilateral nephrectomy [108, 109] showed that males were
predominantly affected.
Similar to man, laboratory animals show a remarkable vari-
ation in susceptibility to the development of FGS. Studies in the
laboratory rat have shown that FGS—like lesions develop spon-
taneously with aging in most rat strains, although a considerable
variability in the severity of the lesions and of the accompany-
ing clinical symptoms has been noted in the different strains
[17—23]. Male rats were found in most studies to be much more
susceptible to develop FGS—like lesions and proteinuria than
females. Sellers et al [110] reported that male rats castrated
before puberty had urinary protein excretion similar to females.
Castration at the adult age prevented proteinuria only partially.
Adult administration of androgen was reported to increase
urinary protein loss both in castrated males and in normal
females. However, the data should be interpreted with caution
since food intake and weight curves during the aforementioned
interventions were not studied. It is well known that male rats
eat more and have larger kidneys than females [111]. Addis et al
[112] reported decreased proteinuria in male rats after adrenal-
ectomy and aggravation of the disease by administration of
thyroid hormone. Again, these authors did not study food
intake or weight curves. Environmental factors may be of
relevance, since Bolton et al [20] showed that germ—free hous-
ing provided relative protection from mesangial accumulation
of 1gM.
As mentioned above, not all rat strains bear the same
susceptibility for the development of FGS—like lesions with
aging or upon intervention (such as partial ablation). Thus, in
addition to food intake, sex hormones and environmental
factors, genetically determined risk factors may be of impor-
tance; these include the number of nephrons per kidney,
systemic blood pressure, the vascular responsivity in relation to
the concentration of circulating vasoactive substances, the
density of receptors on vascular smooth muscle cells, neural
stimulatory status and the characteristics of platelet release
reaction.
Variable susceptibility to FGS in rats
Thus far, two rat strains have been described as relatively
resistant to the development of FGS [113, 114]. Feld et al [113]
compared the development of proteinuria and renal lesions in
male spontaneously hypertensive rats (SHR) made normoten-
sive by treatment with that in male control Wistar Kyoto
(WKY) rats. They followed the two strains for almost two years
and found FGS lesions associated with proteinuria in the
normotensive SHR but not in the WKY. The absence of urinary
abnormalities and glomerular lesions in the two-year old male
WKY rat is remarkable when compared to most other rat
strains studied. Grond et al [114] recently described absence of
proteinuria and of glomerular lesions in the remaining kidney of
one-year-old male PVG/c rats which had been unilaterally
nephrectomized at the age of three months. Male Wistar rats
studied simultaneously had similar weight curves as the PVGIc
rats but revealed FGS lesions in 27% of the glomeruli and
developed overt proteinuria. Upon nephrectomy PVG/c rats
showed no increase in glomerular volume nor in mesangial
uptake of circulating macromolecules, in contrast to the Wistar
rat which showed glomerular volume expansion and a doubling
in mesangial uptake of i.v. administered colloidal carbon [114].
Renal function studies showed that Wistar and PVG/c rats react
to unilateral nephrectomy with a proportional increase in GFR
and RPF.
One explanation for this relative resistance of the PVG/c rat
to the development of FGS could be a 20% higher number of
nephrons per kidney as compared to the Wistar rat [114]. This
explanation however is unsatisfactory, since the two-kidney
male Wistar rat—with 65% more nephrons than the one-kidney
PVGIc rat—was still found to develop proteinuria and FGS—like
lesions at one year [114].
The precise mechanisms underlying the relative resistance of
the WKY and the PVG/c rat to develop FGS are still unclear.
The most attractive explanation is that such animals have a
more "optimal" autoregulation of glomerular hemodynamics,
but other factors—both functional and structural—cannot be
ruled out. Although micropuncture data in the young two-
kidney WKY have revealed normal whole kidney and single
nephron values for filtration rate and for flows and pressures
[115, 116], autoregulatory responses to different stimuli have
not been examined.
The WKY rat is generally used as the normotensive control for
the SHR, which is one of the experimental genetic models of
hypertension. Since the genetic models of hypertension and obe-
sity are most appropriate to study the interrelationship between
genetic differences in vascular tone and especially in afferent and
efferent arteriole reactivity governing glomerular capillary pres-
sures and flows, these models are reviewed below.
Genetic models of hypertension
In laboratory models of genetically determined hypertension
the role of the kidney and the effect of systemic hypertension on
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glomerular microcirculation have been studied most exten-
sively in the SHR and in the Dahi salt sensitive (Dahl S) and
Dahl salt resistant (Dahl R) rats.
Similar to essential hypertension in man [105], genetic hyper-
tension in the SHR, in the Dahl S rat and also in other
laboratory animals is multifactorial in nature and is determined
by genetic and environmental factors [117—119]. Genetic control
of spontaneous or genetic hypertension seems to be polygenic
involving more than one gene dependent upon species and
strain studied [118, 1201. With an increasing number of loci
involved, more generations are needed to breed a 100 per cent
hypertensive population of animals [1211. Genes coding for
hypertension in these experimental models seem not to be part
of the major histocompatibility complex, although this has not
been established in all models [118, 1191.
The spontaneously hypertensive rat
The SHR strain was developed by Okamoto and Aori in 1963
[1221 and showed similar pathophysiological features as the
New Zealand hypertensive rat described five years earlier by
Smirk and Hall [123]. SHR show arterial hypertension as early
as 3 weeks of age, which is associated with increased total
peripheral resistance and a normal cardiac output [124].
Increased vascular resistance is due to constriction of both
the arterial (predominantly small arteries, arterioles and
precapillary sphincters) and venous side of the circulation 1117,
1251. Increased venoconstriction has also been found in humans
with essential hypertension [126, 127] and may lead to increased
capillary filtration, contracted plasma volume and increased
filling pressure of the heart [128, 129]. The latter factor in itself
may induce increased delivery of atrial natriuretic factor, which
has been shown to have a profound effect on glomerular
hemodynamics [130, 131]. Huang et al [131] showed by per-
forming micropuncture studies in rats that infusion of pure
synthetic atrial natriuretic factor induced a considerable in-
crease in whole kidney and single nephron GFR with un-
changed RIP.
As reviewed by Trippodo and Frohlich [117] however, evi-
dence for excessive pressor agents or decreased levels of
depressor substances in relation to the pathogenesis of hyper-
tension in SHR is scarce.
Reports on activation on the renin—angiotensin system in
SHR have yielded conificting results [117]. Brasier et al [132]
recently reported increased renal glomerular angiotensin H
binding in SHR due to the presence of an increased number of
receptors per glomerular cell. Renal prostaglandin E synthesis
has been described as normal in the pre-hypertensive young
SHR and increased in response to progressive development of
hypertension [1331, Greenberg [134] described diminished sen-
sitivity of portal veins from young SHR to prostaglandin E2 and
increased sensitivity to prostaglandins A2, B2, D2 and F2a,
associated with markedly increased prostaglandin synthesis.
Inhibition of converting enzyme and of thromboxane synthe-
tase have been shown to be effective in the treatment of
hypertension in SHR [135—139] indicating that vasoconstrictor
mechanisms can be overcome. Treatment with a triple drug
regimen consisting of reserpine, hydralazine and chlorothiazide
has also been shown to be effective [113].
Glomerular lesions in SHR
In the early phase of hypertension, the kidney shows, like
many other vascularized organs, symptoms of arterial and
arteriolar constriction [117]. Micropuncture studies have shown
that at this point in time afferent arteriolar constriction effec-
tively protects the cortical glomerulus from increased systemic
pressure and that whole kidney and single nephron GFR and
plasma flow as well as intraglomerular hydrostatic pressures are
normal [115, 116]. By modulating systemic arterial pressure,
Arendshorst and Beierwaltes [1151 showed normal autoregu-
latory response in the SHR, largely limited to the preglomerular
vasculature. These studies indicate that enhanced renovascular
resistance in young SHR is primary a physiological response of
afferent arteriolar resistance to increased arterial pressure.
These functional findings explain why in SHR glomerular
lesions do not occur until late in the disease. With time,
autoregulation fails probably due to a loss of nephrons as a
consequence of arteriolar damage and glomerular ischemia or to
the systemic pressure overriding the afferent arteriolar resist-
ance [140]. In the juxtamedullary region, where autoregulatory
mechanisms seem to be impaired and glomeruli are more
exposed to systemic blood pressure [141, 142], early glomenilar
lesions can be seen in the SHR [143]. Feld et al [143] described
FGS—like lesions in juxtamedullary glomeruli associated with
tubular protein casts and overt proteinuria in the presence of
normal subcapsular glomeruli and tubules as measured by
micropuncture. As mentioned above, SHR, maintained
normotensive by triple drug treatment for 100 weeks, still
develop glomerular FGS—like lesions—although somewhat re-
tarded in time [113]. This study 11131 stresses the fact that like
most rats, SHR develops FGS at old age, probably due to failing
autoregulatory mechanisms, which is not linked to systemic
hypertension. Apparently, systemic hypertension only aggra-
vates the lesions.
The Dahl S rat
Based on the observation that high salt intake leads to
hypertension in man and that in experimental conditions not all
rats respond to salt loading with similar changes in blood
pressure, Dahl and co-workers [144, 145] developed by selec-
tive breeding rats that were either resistant (R) or sensitive (S)
to the hypertensive effects of high salt intake.
The central pathogenetic mechanism for the development of
hypertension in the Dahl S rat seems to be the inability of the
kidney in the absence of obvious morphological renal lesions to
excrete sodium rapidly upon salt challenge, a feature that has
also been found in hypertensive subjects and their
normotensive relatives [146]. Sodium itself is a stimulus for
vasoconstriction leading to increased peripheral resistance.
Sodium may act directly on vascular smooth muscle cell
membranes [147] but the central and peripheral sympathetic
nervous system have also been shown to contribute to the
resulting vasoconstriction [148—151]. Tobian et al [152] showed
that DahI S kidneys require a higher arterial perfusion pressure
to excrete the same amount of sodium as Dahl R kidneys. As
long as DahI S are on a low sodium diet, this shift in the
natriuresis curve is of little or no importance, but with higher
sodium intake body sodium will rise acting as a stimulus for
increased blood pressure. Dahl and co-workers showed that the
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Dahi S kidney harbors the primary defect by performing trans-
plant experiments. Dahi S kidneys transplanted to Dahi R rats
transferred sensitivity to salt induced hypertension, whereas
Dahi S rats who had received a Dahl R kidney became resistant
to the hypertensive effect of salt [153].
The molecular or cellular basis for the sodium excretion
defect in Dahl S rats is obscure. Dahi S rats react to salt loading
by vasoconstriction, where Dahi R rats vasodilate [154]. This
difference may be explained on the basis of a 50% reduced
prostaglandin E2 concentration in the renal papilla in the Dahl
S rat as compared to the Dahi R, both during low and high salt
intake [155—158]. Prostaglandin E2 has been shown to retard
sodium reabsorption in the ascending loop of Henle and in the
collecting duct [159—161]. In addition reduced prostaglandin E2
in Dahl S kidneys may be responsible for the 25 to 30% lower
plasma flow in the renal papifia as compared to that in Dahl R
rats [162]. Normally high salt diets will lead to an increase in
papillary blood flow [157]. The inability of the Dahl S rat to
increase papillary blood flow and to excrete sodium on high salt
intake may thus be caused by reduced concentrations of
prostaglandin E2. This hypothesis is supported by studies
aimed at correcting papillary prostaglandin E2 concentration by
feeding Dahi S rats linoleic acid rich diets [163]. Tobian et al
[163] showed that these diets could elevate papillary
prostaglandin E2 concentration considerably, resulting in a
level of prostaglandin E2 similar to that in normal rats. This
elevated prostaglandin E2 was found to be associated with
markedly reduced blood pressure in the Dahl S rat.
Glomerular lesions in Dahl S rats
Morphological and functional studies have shown glomerular
alterations to occur in the hypertensive Dahl S rat at an early
stage in contrast to the SHR [40, 41, 164—167]. FGS—like lesions
can be found throughout the thickness of the cortex, and have
been shown to be progressive with time [164—167]. Micropunc-
ture studies have shown that alterations in intrarenal hemody-
namics are different from those found in SHR, in that in Dahi S
rats afferent and efferent arteriolar resistances are decreased
and that intraglomerular pressures and flows are elevated [40,
41, 165, 166]. Interestingly, Dahl R rats were found to have 15
to 20% more glomeruli per kidney than Dahl S rats [41]. The
interaction between systemic hypertension, elevated intraglo-
merular pressures and mesangial FGS—like lesions in the Dahl S
rat was further investigated by Raij et al [167]. In an elegant
study, they showed that mesangial immune injury in the Dahi S
rat hastens the onset of hypertension, which in turn amplifies
the severity of the glomerular lesions [167].
The studies in the SHR and Dahl rats and in experimental
non-genetic models of hypertension clearly illustrate the varia-
tion in glomerular damage that can occur. As discussed by Raij
et al [167], these animal models may provide an explanation for
the different patterns of vascular and glomerular injury seen in
human forms of glomerulonephritis and hypertension [168].
Crucial in the hypertensive models described above is the
protection or lack of protection of the glomerular capillary
network from the systemic pressures by afferent arteriolar
constriction. Relaxation of the afferent arteriole as an adapta-
tion to loss of functional renal mass, to high protein levels or to
vasoactive or other stimuli will have a harmful effect on the
glomerular circulation. Evidence for this mechanism can also
be derived from studies in genetic models of obesity.
Genetic models of obesity
In genetic models of obesity with or without hypertension
FGS—like lesions occur frequently and early in association with
proteinuria and loss of renal function apart from arterial and
arteriolar changes.
In the early sixties, Zucker and Zucker [47] described a
mutant rat strain that exhibited hyperphagia, hyperlipidemia,
proteinuria and renal disease. Hypertension was found later in
the disease and was attributed to the renal damage [47—49].
Glomerular lesions were described as glomerulonephrosis and
pictures shown resemble FGS—like lesions. Similar lesions were
found in rats with experimentally induced hypothalamic
hyperphagia [169]. Koletsky [50] described the combination of
obesity, hyperlipidemia and hypertension as an inherited
homozygous recessive trait in a hybrid derived from crossing
the SHR with the normotensive Sprague-Dawley rat. The obese
animals being homozygous for the recessive gene showed
hyperphagia, marked hypertriglyceridemia and moderate
hypercholesterolemia, and signs of obesity. Hypertension and
proteinuria developed at six weeks of age. Body weight was
found to rise to 900 gm in males and 700 gm in females within a
year. At that time, urinary protein loss amounted to a maximum
of 900 mg per 24 hours. Life span was only half of that of the
non-obese siblings and renal failure was the most common
cause of death. Kidneys showed progressive glomerular pathol-
ogy, characterized as FGS—like lesions. The non-obese siblings,
eating less than half of the amount the obese rats would
consume, were found to exhibit no signs of hyperphagia or
hyperlipidemia. Although they suffered from hypertension to
the same extent as the obese animals, this was not associated
with proteinuria or the development of FGS—like lesions [50,
52]. A hypothalamus—pituitary gland abnormality leading to
hyperphagia is the most likely cause for the obesity and
hyperlipidemia in these genetically obese rats. The develop-
ment of hyperphagia, lipid abnormalities, obesity and protein-
uria in the Koletsky rats was found to be completely prevented
by hypophysectomy [51]. Low calorie diets also prevented
obesity and renal failure and lowered urinary protein excretion
to almost normal levels. Light microscopy revealed absence of
FGS—like lesions in hypophysectomized and low calorie diet
animals [51]. Systemic blood pressure was found to be unaf-
fected in animals fed the low calorie diet and in one third of the
hypophysectomized rats. This clearly indicates that FGS—like
lesions, proteinuria and renal failure in these rats are deter-
mined by factors involving hyperphagia, obesity and
hyperlipidemia and not by elevated blood pressure [51, 52].
The pituitary has been shown to influence systemic blood
pressure and renal hemodynamics in man [170] and in experi-
mental animals [171]. Hypophysectomy causes a fall in systolic
and diastolic blood pressure, a decrease in renal plasma flow
and glomerular filtration rate, a decrease in cardiac output and
an increase in peripheral vascular resistance [170—173]. Urinary
excretion of protein in the experimental model of
aminonucleoside nephrosis in the rat was found to be lowered
by hypophysectomy [174]. Recently, hypophysectomy was
reported to have a protective effect on the development of
functional and structural glomerular abnormalities in the rem-
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nant kidney [175]. Micropuncture studies revealed a normaliza-
tion of intraglomerular pressures and flows after hypophysec-
tomy in partially nephrectomized rats [175j.
It is uncertain whether this effect of hypophysectomy is due
to the loss of growth hormone which has an enhancing effect on
renal function [170j, to lowering systemic blood pressure or to
some effect on lipid metabolism. In the obese rats, the protec-
tive effect of hypophysectomy has been largely attributed to the
reduced intake of food, since feeding intact animals a low
calorie diet was found to have the same effect despite the
presence of hypertension and intact levels of pituitary gland
hormones [51].
Based on these findings it seems likely that in the obese
animals, the central mechanism in the pathogenesis of FGS is
the high food intake inducing vasodilatation, thus opening up
the glomes-ular capillary bed to systemic blood pressure. Sys-
temic blood pressure—already elevated in the Koletsky
strain—combined with high plasma concentration of lipids [89,
176—178] may result in progressive glomerular damage and
subsequent renal failure.
Other genetically determined factors which have as yet not been
studied in these animals may contribute to this chain of events,
e.g.: a low number of nephrons as was found in the salt sensitive
Dahl strain of rats; platelet abnormalities as were established in
the Fawn Hooded rat [179], which developed FGS [16, 180] and
hypertension [181]; and vascular responsivity.
Conclusions
Some of the factors leading to FOS appear to be genetically
determined and may induce through several pathways the
characteristic glomerular lesions of capillary distension and
thrombosis, and segmental hyalinosis and sclerosis. Important
in this respect are intraglomerular hemodynamic alterations
governed by vascular tone and responsivity, but also structural,
metabolic and coagulation factors may be involved. Future
studies on the genetically determined risk factors predisposing
to the development of FGS in man and laboratory animals may
allow us to predict the glomerular response to possibly delete-
rious events such as partial loss of functional renal mass.
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